A phase II study of stereotactic body radiation therapy in patients with T1N0M0 non-small cell lung cancer (JCOG0403)

A phase II study of stereotactic body radiation therapy in patients with T1N0M0 non-small cell lung cancer (JCOG0403) - A phase II study of stereotactic body radiation therapy in patients with T1N0M0 non-small cell lung cancer (JCOG0403)

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-C000000029

Enrollment

169

Registered

2005-07-28

Start date

2004-07-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

T1N0M0 non-small cell lung cancer

Interventions

stereotactic body radiation therapy

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1.Histologically or transbronchoscopic cytologically confirmed non-small cell lung cancer 2.Stage IA with images within 28 days 3.No other intrathoracic lesions 4.Dose constraints of the organs at risk seem to be limited within range 5.Operable (Standard or Limited surgery) or Inoperable 6.Age>=20 7.No previous thoracic radiation 8.No previous chemotherapy 9.ECOG PS=0-2 10.Respiratory function (<=14 days) PaO2>=60 torr FEV1.0>=700 ml 11.Written informed consent

Exclusion criteria

Exclusion criteria: 1. No apparent interstitial pneumonitis and fibrosis 2. No active inflamation without oral drugs 3. No double cancer 4. No pregnancy 5. No psychiatric disorder 6. No steroid administration

Design outcomes

Primary

Measure	Time frame
3-years overall survival	—

Countries

Japan

Contacts

Public ContactYasushi Nagata, M.D.

JCOG0403 Coordinating Office Division of Radiation Oncology, Hiroshima University Hospital

JCOG_sir@ml.jcog.jp

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026